Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors: Aurora Biolabs Launches First Binding Assay for KRAS G12D/CypA/Inhibitor Screening
Aurora Biolabs, a recognized leader in RAS-targeted protein production, assay development, and co-crystal structure determination, has announced the launch of the industry’s first binding assay for screening KRAS G12D/Cyclophilin A (CypA)/inhibitor tri-complexes. This milestone represents a significant leap in accelerating drug discovery for one of the most critical oncogenic targets in cancer biology.
KRAS mutations—particularly G12D—are frequently implicated in lung, colon, and pancreatic cancers, locking RAS proteins in a constitutively active GTP-bound "ON" state. These mutant proteins drive unchecked cell proliferation and tumor growth by persistently activating downstream effector pathways. While RAS has long been considered "undruggable," the emergence of tri-complex inhibitors offers a transformative approach. Revolution Medicines has pioneered this field with macrocyclic compounds that first bind Cyclophilin A, then selectively engage RAS(ON) to form a tri-complex that sterically blocks effector interaction.
To support the development of this next generation of RAS(ON) inhibitors, Aurora Biolabs now offers a proprietary binding assay capable of quantifying the formation of the KRAS G12D/CypA/inhibitor tri-complex. This assay delivers rapid, reliable data essential for screening compound libraries and optimizing drug candidates targeting the oncogenic RAS state. It complements Aurora's extensive toolkit, including high-quality KRAS mutant proteins, assay kits, and structure determination services, forming a complete solution for RAS-targeted drug discovery.
“Our goal is to deliver the fastest and most accurate tools to support KRAS-targeted therapy development,” said Dr. May Zheng, the project manager of Aurora Biolabs. “By enabling researchers to directly assess tri-complex formation in vitro, we are bridging a critical gap in translational oncology and accelerating the path toward effective therapies for KRAS-driven cancers.”
Aurora Biolabs invites collaboration with biotech and pharmaceutical partners aiming to explore or expand their RAS inhibitor pipelines. With the introduction of this cutting-edge assay, the company solidifies its position at the forefront of RAS drug discovery support.
For more information, visit www.aurorabiolabs.com or contact the Aurora Biolabs team at
